Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline

Eikon Therapeutics获得3.507亿美元D轮融资，以推进临床阶段项目和未来研发管线。

HAYWARD, Calif., February 26, 2025-- Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug discovery and development, today announced the initial closing of a $350.7 million Series D financing.

加利福尼亚州海沃德，2025年2月26日——Eikon Therapeutics, Inc.是一家处于关键阶段的生物技术公司，致力于将先进的工程技术与前沿的分子和细胞生物学相结合，以加速药物的发现和开发。该公司今天宣布已完成3.507亿美元的D轮融资的初步交割。

Since its founding in 2019, Eikon Therapeutics has privately raised in excess of $1.1 billion to support its mission of developing new medicines to address grievous illnesses..

自2019年成立以来，Eikon Therapeutics已私下筹集超过11亿美元，以支持其开发治疗严重疾病的新药的使命。

The financing round was led by Eikon’s existing investors, with participation from new investors. The investment syndicate is composed of top mutual funds, sovereign wealth funds, and healthcare and technology-focused venture firms including Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, funds and accounts advised by T.

本轮融资由 Eikon 现有投资者领投，新投资者也参与其中。投资银团由顶级共同基金、主权财富基金以及专注于医疗保健和技术的风险投资公司组成，包括 Lux Capital、Alexandria Venture Investments、AME Cloud Ventures、The Column Group、E15 VC、Foresite Capital、General Catalyst、Soros Capital、StepStone Group，以及由 T. 提供建议的基金和账户。

Rowe Price Associates, Inc., and UC Investments (Office of the Chief Investment Officer of the Regents of the University of California), among others..

普信集团、加州大学投资部（加州大学董事会首席投资官办公室）等。

“Eikon has made remarkable progress in advancing a pivotal-stage clinical pipeline and early-stage development program powered by our single-molecule tracking technology and the deep expertise of our multidisciplinary team. With clinical studies now operating in 28 countries, across 5 continents, we are accelerating the development of much-needed therapies while continuing to expand our research and development capabilities,” said Roger M.

“Eikon 在推进关键阶段的临床管线和早期开发计划方面取得了显著进展，这得益于我们的单分子追踪技术和多学科团队的深厚专业知识。随着临床研究现在在 28 个国家、5 大洲开展，我们正在加速开发急需的治疗方法，同时继续扩展我们的研发能力，”Roger M. 表示。

Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics. “This financing provides the resources necessary to build a fully-integrated, 21st-century biotechnology company that leverages advanced computing, data sciences, and decades of experience in bringing innovative medicines to patients.

Perlmutter，医学博士，哲学博士，Eikon Therapeutics公司首席执行官兼董事会主席。“此次融资提供了必要的资源，用于打造一家完全整合的21世纪生物技术公司，利用先进的计算技术、数据科学以及数十年将创新药物带给患者的丰富经验。

The continued support of our world-class syndicate of investors is a testament both to the progress we have already made, and to the confidence of investors in our ability to deliver important new medicines for the world.”.

“我们的一流投资者集团对我们的持续支持，既证明了我们已经取得的进展，也体现了投资者对我们能够为世界提供重要新药的信心。”

Eikon’s clinical portfolio is anchored by its lead program, EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 now in a Phase III trial for advanced melanoma. EIK1001 has demonstrated both single-agent efficacy and promising in-combination activity with anti-PD-(L)1 agents across multiple tumor types.

Eikon的临床产品组合以其主导项目EIK1001为核心，这是一种系统性给药的Toll样受体7和8的共激动剂，目前正处于针对晚期黑色素瘤的III期试验中。EIK1001已显示出单药疗效，并在多种肿瘤类型中与抗PD-(L)1药物联合使用时表现出良好的活性。

In parallel, the company is advancing EIK1003, a highly selective PARP1 inhibitor currently undergoing Phase 1 evaluation in patients with breast, ovarian, prostate, or pancreatic cancers, and EIK1004, a central nervous system-penetrant PARP1-selective inhibitor poised to initiate Phase 1 studies targeting brain cancers..

同时，该公司正在推进EIK1003，这是一种高选择性的PARP1抑制剂，目前正在进行针对乳腺癌、卵巢癌、前列腺癌或胰腺癌患者的1期临床评估，以及EIK1004，一种能够穿透中枢神经系统的PARP1选择性抑制剂，即将启动针对脑癌的1期研究。

Eikon’s early-stage pipeline features, among other undisclosed candidates, two androgen receptor antagonists and an internally derived WRN inhibitor (EIK1005) that is being studied for its potential as a therapy for patients with MSI-high and other DNA repair–deficient cancers.

Eikon的早期研发管线包括两种雄激素受体拮抗剂和一种内部研发的WRN抑制剂（EIK1005），后者正被研究用于治疗MSI高和其他DNA修复缺陷型癌症的潜力，此外还有其他未披露的候选药物。

“Eikon has engineered a next-generation drug discovery engine that seamlessly integrates automation, high-performance computing, and advanced data science to transform how new medicines are developed,” said Lux Capital Co-founder and Managing Partner Josh Wolfe. “By harnessing its proprietary single molecule tracking technology, Eikon is uncovering biological processes in living cells with an unprecedented level of precision, generating insights at a pace that was previously out of reach.

“Eikon 开发了一个下一代药物发现引擎，无缝整合了自动化、高性能计算和先进数据科学，从而变革新药研发的方式，”Lux Capital联合创始人兼管理合伙人Josh Wolfe表示。“通过利用其专有的单分子追踪技术，Eikon 正在以前所未有的精确度揭示活细胞中的生物过程，以过去无法企及的速度生成见解。"

With a skilled leadership team that is deeply experienced in bringing groundbreaking therapies to patients, Eikon is setting a new standard for innovation in biotechnology.”.

凭借一支在为患者带来开创性疗法方面经验丰富的领导团队，Eikon 正在为生物技术创新树立新的标准。

Eikon Therapeutics will participate in the upcoming TD Cowen Healthcare Conference in Boston, March 3-5, 2025.

Eikon Therapeutics 将参加2025年3月3日至5日在波士顿举行的TD Cowen医疗保健会议。

About Eikon Therapeutics

关于Eikon Therapeutics

Eikon Therapeutics is advancing breakthrough therapies through the purposeful integration of science and engineering. Our proprietary discovery technologies leverage Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to people suffering from grievous illness.

Eikon Therapeutics 正在通过科学与工程的有机结合推动突破性疗法的发展。我们的专有发现技术利用了诺贝尔奖获奖的超分辨率显微镜、先进的工程设计和高性能计算，以可视化和测量活细胞中蛋白质的实时运动，目标是为遭受严重疾病困扰的人们带来重要的新药。

Eikon operates from its facilities in California, New Jersey, and New York, and can be found online at www.EikonTx.com or LinkedIn..

Eikon 在其位于加利福尼亚州、新泽西州和纽约的工厂开展业务，也可以在 www.EikonTx.com 或 LinkedIn 上找到。

Contact:

联系人：

Media Contact

媒体联系人

Colin Sanford

科林·桑福德

colin@bioscribe.com

colin@bioscribe.com